Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/34595
Title: | Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years | Authors: | Buiten, Rosaly A. Ploumen, Eline H. Zocca, Paolo Doggen, Carine J.M. Jessurun, Gillian A.J. Schotborgh, Carl E. Roguin, Ariel Danse, Peter W. BENIT, Edouard Aminian, Adel van Houwelingen, K. Gert Schramm, Alexander R. Stoel, Martin G. Somi, Samer Hartmann, Marc Linssen, Gerard C.M. von Birgelen, Clemens |
Issue Date: | 2020 | Source: | JACC: cardiovascular interventions (Print), 13 (9) , p. 1100 -1109 | Abstract: | OBJECTIVES The aim of this study was to assess 2-year safety and efficacy of the current-generation thin composite-wire-strut durable-polymer Resolute Onyx zotarolimus-eluting stent (ZES), compared with the ultrathin-strut biodegradable-polymer Orsiro sirolimus-eluting stent (SES) in all-comers and a pre-specified small-vessel subgroup analysis. BACKGROUND The Resolute Onyx ZES is widely used in clinical practice, but no follow-up data beyond 1 year have been published. The randomized BIONYX (Bioresorbable Polymer-Coated Orsiro Versus Durable Polymer-Coated Resolute Onyx Stents) trial (NCT02508714) established the noninferiority of ZES versus SES regarding target vessel failure (TVF) rates. METHODS A total of 2,488 all-comer patients were treated at 7 coronary intervention centers in Belgium, Israel, and the Netherlands. The main endpoint, TVF, was a composite of safety (cardiac death or target vessel-related myocardial infarction) and efficacy (clinically indicated target vessel revascularization). Two-year follow-up data were analyzed using Kaplan-Meier methods. RESULTS Two-year follow-up data were available for 2,460 of 2,488 patients (98.9%). TVF occurred in 93 of 1,243 patients (7.6%) assigned to ZES versus 87 of 1,245 patients (7.1%) assigned to SES (log-rank p = 0.66). There was no significant between-stent difference in individual components of this endpoint. The incidence of definite-or-probable stent thrombosis was low for both treatment arms (0.4% vs. 1.1%; log-rank p = 0.057). In patients stented in small vessels, there was no between-stent difference (TVF 8.2% vs. 8.7% [log-rank p = 0.75], target lesion revascularization 4.0% vs. 4.4% [log-rank p = 0.77]). CONCLUSIONS At 2-year follow-up, the novel thin composite-wire-strut durable-polymer Resolute Onyx ZES showed in all-comers similar safety and efficacy compared with the ultrathin cobalt-chromium-strut biodegradable-polymer Orsiro SES. The analysis of patients who were treated in small vessels also suggested no advantage for either stent. (c) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY- NC-ND license ( http://creativecommons.org/licenses/by- nc-nd/4.0/). | Document URI: | http://hdl.handle.net/1942/34595 | ISSN: | 1936-8798 | e-ISSN: | 1876-7605 | DOI: | 10.1016/j.jcin.2020.01.230 | ISI #: | WOS:000531821900017 | Category: | A1 | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S1936879820304386-main.pdf Restricted Access | Published version | 1.27 MB | Adobe PDF | View/Open Request a copy |
WEB OF SCIENCETM
Citations
27
checked on Oct 14, 2024
Page view(s)
46
checked on Sep 7, 2022
Download(s)
6
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.